Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial

Mark A. Hlatky, Derek B. Boothroyd, Kathryn A. Melsop, Laurence Kennedy, Charanjit Rihal, William J. Rogers, Lakshmi Venkitachalam, Maria M. Brooks

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

BACKGROUND-: The economic outcomes of clinical management strategies are important in assessing their value to patients. METHODS AND RESULTS-: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized patients with type 2 diabetes mellitus and angiographically documented, stable coronary disease to strategies of (1) prompt revascularization versus medical therapy with delayed revascularization as needed to relieve symptoms and (2) insulin sensitization versus insulin provision. Before randomization, the physician declared whether coronary artery bypass grafting or percutaneous coronary intervention would be used if the patient were assigned to revascularization. We followed 2005 patients for medical utilization and costs and assessed the cost-effectiveness of these management strategies. Medical costs were higher for revascularization than medical therapy, with a significant interaction with the intended method of revascularization (P<0.0001). In the coronary artery bypass grafting stratum, 4-year costs were $80 900 for revascularization versus $60 600 for medical therapy (P<0.0001). In the percutaneous coronary intervention stratum, costs were $73 400 for revascularization versus $67 800 for medical therapy (P<0.02). Costs also were higher for insulin sensitization ($71 300) versus insulin provision ($70 200). Other factors that significantly (P<0.05) and independently increased cost included insulin use and dose at baseline, female sex, white race, body mass index ≥ 30, and lbuminuria. Cost-effectiveness based on 4-year data favored the strategy of medical therapy over prompt revascularization and the strateg of insulin provision over insulin sensitization. Lifetime projections of cost-effectiveness showed that medical theray was cost-effective compared with revascularization in the percutaneous coronary intervention stratum ($600 per life-year added) with high confidence. Lifetime projections suggest that revascularization may be cost-effective in the coronary artery bypass grafting stratum ($47 000 per life-year added) but with lower confidence. CONCLUSIONS-: Prompt coronary revascularization significantly increases costs among patients with type 2 diabetes mellitus and stable coronary disease. The strategy of medical therapy (with delayed revascularization as needed) appears to be cost-effective compared with the strategy of prompt coronary revascularization among patients identified a priori as suitable for percutaneous coronary intervention.

Original languageEnglish (US)
Pages (from-to)2550-2558
Number of pages9
JournalCirculation
Volume120
Issue number25
DOIs
StatePublished - Dec 2009

Fingerprint

Angioplasty
Type 2 Diabetes Mellitus
Coronary Artery Disease
Economics
Costs and Cost Analysis
Insulin
Percutaneous Coronary Intervention
Coronary Artery Bypass
Cost-Benefit Analysis
Coronary Disease
Therapeutics
Random Allocation
Body Mass Index
Physicians

Keywords

  • Angioplasty
  • Cost-benefit analysis
  • Diabetes mellitus
  • Revascularization
  • Surgery

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial. / Hlatky, Mark A.; Boothroyd, Derek B.; Melsop, Kathryn A.; Kennedy, Laurence; Rihal, Charanjit; Rogers, William J.; Venkitachalam, Lakshmi; Brooks, Maria M.

In: Circulation, Vol. 120, No. 25, 12.2009, p. 2550-2558.

Research output: Contribution to journalArticle

Hlatky, Mark A. ; Boothroyd, Derek B. ; Melsop, Kathryn A. ; Kennedy, Laurence ; Rihal, Charanjit ; Rogers, William J. ; Venkitachalam, Lakshmi ; Brooks, Maria M. / Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial. In: Circulation. 2009 ; Vol. 120, No. 25. pp. 2550-2558.
@article{5a0c6cefd5224c7197fe151ed066fb78,
title = "Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial",
abstract = "BACKGROUND-: The economic outcomes of clinical management strategies are important in assessing their value to patients. METHODS AND RESULTS-: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized patients with type 2 diabetes mellitus and angiographically documented, stable coronary disease to strategies of (1) prompt revascularization versus medical therapy with delayed revascularization as needed to relieve symptoms and (2) insulin sensitization versus insulin provision. Before randomization, the physician declared whether coronary artery bypass grafting or percutaneous coronary intervention would be used if the patient were assigned to revascularization. We followed 2005 patients for medical utilization and costs and assessed the cost-effectiveness of these management strategies. Medical costs were higher for revascularization than medical therapy, with a significant interaction with the intended method of revascularization (P<0.0001). In the coronary artery bypass grafting stratum, 4-year costs were $80 900 for revascularization versus $60 600 for medical therapy (P<0.0001). In the percutaneous coronary intervention stratum, costs were $73 400 for revascularization versus $67 800 for medical therapy (P<0.02). Costs also were higher for insulin sensitization ($71 300) versus insulin provision ($70 200). Other factors that significantly (P<0.05) and independently increased cost included insulin use and dose at baseline, female sex, white race, body mass index ≥ 30, and lbuminuria. Cost-effectiveness based on 4-year data favored the strategy of medical therapy over prompt revascularization and the strateg of insulin provision over insulin sensitization. Lifetime projections of cost-effectiveness showed that medical theray was cost-effective compared with revascularization in the percutaneous coronary intervention stratum ($600 per life-year added) with high confidence. Lifetime projections suggest that revascularization may be cost-effective in the coronary artery bypass grafting stratum ($47 000 per life-year added) but with lower confidence. CONCLUSIONS-: Prompt coronary revascularization significantly increases costs among patients with type 2 diabetes mellitus and stable coronary disease. The strategy of medical therapy (with delayed revascularization as needed) appears to be cost-effective compared with the strategy of prompt coronary revascularization among patients identified a priori as suitable for percutaneous coronary intervention.",
keywords = "Angioplasty, Cost-benefit analysis, Diabetes mellitus, Revascularization, Surgery",
author = "Hlatky, {Mark A.} and Boothroyd, {Derek B.} and Melsop, {Kathryn A.} and Laurence Kennedy and Charanjit Rihal and Rogers, {William J.} and Lakshmi Venkitachalam and Brooks, {Maria M.}",
year = "2009",
month = "12",
doi = "10.1161/CIRCULATIONAHA.109.912709",
language = "English (US)",
volume = "120",
pages = "2550--2558",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "25",

}

TY - JOUR

T1 - Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial

AU - Hlatky, Mark A.

AU - Boothroyd, Derek B.

AU - Melsop, Kathryn A.

AU - Kennedy, Laurence

AU - Rihal, Charanjit

AU - Rogers, William J.

AU - Venkitachalam, Lakshmi

AU - Brooks, Maria M.

PY - 2009/12

Y1 - 2009/12

N2 - BACKGROUND-: The economic outcomes of clinical management strategies are important in assessing their value to patients. METHODS AND RESULTS-: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized patients with type 2 diabetes mellitus and angiographically documented, stable coronary disease to strategies of (1) prompt revascularization versus medical therapy with delayed revascularization as needed to relieve symptoms and (2) insulin sensitization versus insulin provision. Before randomization, the physician declared whether coronary artery bypass grafting or percutaneous coronary intervention would be used if the patient were assigned to revascularization. We followed 2005 patients for medical utilization and costs and assessed the cost-effectiveness of these management strategies. Medical costs were higher for revascularization than medical therapy, with a significant interaction with the intended method of revascularization (P<0.0001). In the coronary artery bypass grafting stratum, 4-year costs were $80 900 for revascularization versus $60 600 for medical therapy (P<0.0001). In the percutaneous coronary intervention stratum, costs were $73 400 for revascularization versus $67 800 for medical therapy (P<0.02). Costs also were higher for insulin sensitization ($71 300) versus insulin provision ($70 200). Other factors that significantly (P<0.05) and independently increased cost included insulin use and dose at baseline, female sex, white race, body mass index ≥ 30, and lbuminuria. Cost-effectiveness based on 4-year data favored the strategy of medical therapy over prompt revascularization and the strateg of insulin provision over insulin sensitization. Lifetime projections of cost-effectiveness showed that medical theray was cost-effective compared with revascularization in the percutaneous coronary intervention stratum ($600 per life-year added) with high confidence. Lifetime projections suggest that revascularization may be cost-effective in the coronary artery bypass grafting stratum ($47 000 per life-year added) but with lower confidence. CONCLUSIONS-: Prompt coronary revascularization significantly increases costs among patients with type 2 diabetes mellitus and stable coronary disease. The strategy of medical therapy (with delayed revascularization as needed) appears to be cost-effective compared with the strategy of prompt coronary revascularization among patients identified a priori as suitable for percutaneous coronary intervention.

AB - BACKGROUND-: The economic outcomes of clinical management strategies are important in assessing their value to patients. METHODS AND RESULTS-: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized patients with type 2 diabetes mellitus and angiographically documented, stable coronary disease to strategies of (1) prompt revascularization versus medical therapy with delayed revascularization as needed to relieve symptoms and (2) insulin sensitization versus insulin provision. Before randomization, the physician declared whether coronary artery bypass grafting or percutaneous coronary intervention would be used if the patient were assigned to revascularization. We followed 2005 patients for medical utilization and costs and assessed the cost-effectiveness of these management strategies. Medical costs were higher for revascularization than medical therapy, with a significant interaction with the intended method of revascularization (P<0.0001). In the coronary artery bypass grafting stratum, 4-year costs were $80 900 for revascularization versus $60 600 for medical therapy (P<0.0001). In the percutaneous coronary intervention stratum, costs were $73 400 for revascularization versus $67 800 for medical therapy (P<0.02). Costs also were higher for insulin sensitization ($71 300) versus insulin provision ($70 200). Other factors that significantly (P<0.05) and independently increased cost included insulin use and dose at baseline, female sex, white race, body mass index ≥ 30, and lbuminuria. Cost-effectiveness based on 4-year data favored the strategy of medical therapy over prompt revascularization and the strateg of insulin provision over insulin sensitization. Lifetime projections of cost-effectiveness showed that medical theray was cost-effective compared with revascularization in the percutaneous coronary intervention stratum ($600 per life-year added) with high confidence. Lifetime projections suggest that revascularization may be cost-effective in the coronary artery bypass grafting stratum ($47 000 per life-year added) but with lower confidence. CONCLUSIONS-: Prompt coronary revascularization significantly increases costs among patients with type 2 diabetes mellitus and stable coronary disease. The strategy of medical therapy (with delayed revascularization as needed) appears to be cost-effective compared with the strategy of prompt coronary revascularization among patients identified a priori as suitable for percutaneous coronary intervention.

KW - Angioplasty

KW - Cost-benefit analysis

KW - Diabetes mellitus

KW - Revascularization

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=73949135481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949135481&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.109.912709

DO - 10.1161/CIRCULATIONAHA.109.912709

M3 - Article

C2 - 19920002

AN - SCOPUS:73949135481

VL - 120

SP - 2550

EP - 2558

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 25

ER -